RNA Therapeutics Meeting
Join us for an exciting event focused on RNA therapeutics and hosted by the Crick Science Entrepreneur Network.
🗓️ Wednesday, May 15th 2024
📍The Francis Crick Institute
Featuring talks from a diverse lineup of speakers representing academia, biotech startups, and VC, our event will showcase the pivotal role RNA plays in revolutionising healthcare. From bench to bedside, we'll explore cutting-edge RNA research and its practical applications, inspiring scientists to venture into the field of RNA therapeutics.
⏰ Event Schedule (time GMT):
2:30 - 3:00 pm - Arrival and Registration
3:00 - 3:45 pm - Session 1 Talks
15 min Short Break
4:00 - 4:45 pm - Session 2 Talks
15 min Short Break
5:00 - 6:00 pm - Panel Discussion and Q&A
6:00 - 7:00 pm - Networking Session
🧬 Participating Speakers:
Dr Yaara Ofir-Rosenfeld, Director of Translation Oncology at STORM Therapeutics
Aurélie Lacroix, Senior Scientist at Sixfold Bioscience
Dr Alex Debacker, Principal Oligonucleotide Chemist at E-therapeutics
Asif Tulah, Business Development Manager at CPI
Dr Sara Aguti, Senior Research Fellow at UCL Gene Therapy Accelerator Centre
Prof Robin Shattock, Head of Mucosal Infection and Immunity at Imperial College London
Dr Peter Oliver, Head of Biology at Nucleic Acid Therapy Accelerator
Dr Johnathan Matlock, Co-Founder at Empirical Ventures
Dr Loïc Roux, Co-Founder at OligoTune
Don't miss this opportunity to connect with leading experts, entrepreneurs, and innovators in the field of RNA therapeutics. Reserve your spot today and be part of the future of healthcare!
Who are the Crick Science Entrepreneur Network (CSEN)?
Established in 2021, CSEN works alongside The Francis Crick Institute Translation Team to promote and develop entrepreneurship within the scientific community. CSEN aims to bring together researchers at all career stages to learn about the translation and commercialisation potential of their research. Our events share the experiences and journeys of founders of academic spinout companies or scientists who have transitioned to a career in innovation, venture capital or technology transfer.